Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
13 10 2020
Historique:
received: 12 05 2020
accepted: 03 09 2020
entrez: 9 10 2020
pubmed: 10 10 2020
medline: 15 5 2021
Statut: ppublish

Résumé

Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with the most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis. The interval between diagnosis and leukemic evolution is highly variable, from a few years to >20 years. We performed a molecular evaluation of 49 leukemic transformations of PV and ET by targeted next-generation sequencing. Using a hierarchical classification, we identified 3 molecular groups associated with a distinct time to leukemic transformation. Short-term transformations were mostly characterized by a complex molecular landscape and mutations in IDH1/2, RUNX1, and U2AF1 genes, whereas long-term transformations were associated with mutations in TP53, NRAS, and BCORL1 genes. Studying paired samples from chronic phase and transformation, we detected some mutations already present during the chronic phase, either with a significant allele burden (short-term transformation) or with a very low allele burden (especially TP53 mutations). However, other mutations were not detected even 1 year before leukemic transformation. Our results suggest that the leukemic transformation of PV and ET may be driven by distinct time-dependent molecular mechanisms.

Identifiants

pubmed: 33035330
pii: S2473-9529(20)31222-2
doi: 10.1182/bloodadvances.2020002271
pmc: PMC7556129
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4887-4897

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2020 by The American Society of Hematology.

Références

Ann Hematol. 2018 Mar;97(3):443-451
pubmed: 29181548
Ann Hematol. 2017 May;96(5):725-732
pubmed: 28161773
Br J Haematol. 2017 Sep;178(5):764-771
pubmed: 28542718
Blood. 2005 Apr 1;105(7):2664-70
pubmed: 15585653
J Clin Oncol. 2017 Mar 20;35(9):947-954
pubmed: 28297629
Blood. 2008 Aug 15;112(4):1402-12
pubmed: 18515659
Genes Chromosomes Cancer. 2012 Aug;51(8):743-55
pubmed: 22489043
Blood. 2008 Sep 1;112(5):1628-37
pubmed: 18566326
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Leukemia. 2018 Feb;32(2):450-461
pubmed: 28744014
Blood. 2012 May 10;119(19):4480-5
pubmed: 22431577
Leukemia. 2007 Feb;21(2):270-6
pubmed: 17170720
Science. 1997 Jan 17;275(5298):343-9
pubmed: 8994024
Blood. 2014 Apr 3;123(14):2220-8
pubmed: 24478400
Blood Adv. 2018 Feb 27;2(4):370-380
pubmed: 29467191
Leuk Lymphoma. 2018 Dec;59(12):2812-2820
pubmed: 29616837
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615
pubmed: 25037629
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Blood Adv. 2018 Oct 23;2(20):2658-2671
pubmed: 30327374
Haematologica. 2008 Nov;93(11):1645-51
pubmed: 18790799
Haematologica. 2019 Apr;104(4):e134-e137
pubmed: 30337359
Am J Hematol. 2017 Sep;92(9):885-891
pubmed: 28543356
Am J Hematol. 2018 Mar;93(3):330-338
pubmed: 29148089
Nature. 2014 Aug 7;512(7512):78-81
pubmed: 25043017
J Clin Oncol. 2011 Aug 10;29(23):3179-84
pubmed: 21747083
Br J Haematol. 2020 Apr;189(2):291-302
pubmed: 31945802
BMC Bioinformatics. 2009 Jan 26;10:34
pubmed: 19171069
Blood. 2005 Feb 1;105(3):973-7
pubmed: 15388582
Nature. 2015 Feb 26;518(7540):552-555
pubmed: 25487151
Blood Adv. 2016 Nov 22;1(1):21-30
pubmed: 29296692
Blood. 2010 Apr 8;115(14):2891-900
pubmed: 20008300
Leukemia. 2013 Sep;27(9):1874-81
pubmed: 23739289
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5401-10
pubmed: 25516983
Leukemia. 2018 May;32(5):1200-1210
pubmed: 29459662
Haematologica. 2017 Jan;102(1):e11-e14
pubmed: 27742771
Leukemia. 2010 Oct;24(10):1713-8
pubmed: 20724988
Blood Adv. 2019 Feb 12;3(3):320-332
pubmed: 30709863
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
pubmed: 9843981
N Engl J Med. 2018 Oct 11;379(15):1416-1430
pubmed: 30304655
N Engl J Med. 2011 Feb 3;364(5):488-90
pubmed: 21288114
J Clin Oncol. 2011 Oct 10;29(29):3907-13
pubmed: 21911721
Biol Blood Marrow Transplant. 2020 Jun;26(6):1160-1170
pubmed: 32119970
Leukemia. 2009 May;23(5):905-11
pubmed: 19262601
Best Pract Res Clin Haematol. 2019 Mar;32(1):65-73
pubmed: 30927977

Auteurs

Damien Luque Paz (D)

Université d'Angers, Inserm, CRCINA, Angers, France.
Unité de Formation et de Recherche (UFR) Santé, Université d'Angers, Angers, France.
Laboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.

Rébecca Jouanneau-Courville (R)

Laboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.

Jérémie Riou (J)

INSERM 1066, Micro et Nanomédecines Translationnelles (MiNT), Université d'Angers, Angers, France.

Jean-Christophe Ianotto (JC)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service d'Hématologie Clinique, Centre Hospitalier Régional et Universitaire (CHRU) Brest, Brest, France.

Françoise Boyer (F)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service des Maladies du Sang, CHU Angers, Angers, France.

Aurélie Chauveau (A)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Laboratoire d'Hématologie, CHRU Brest, Brest, France.
Faculté de Médecine, Université de Bretagne Occidentale, Brest, France.

Maxime Renard (M)

Université d'Angers, Inserm, CRCINA, Angers, France.
Unité de Formation et de Recherche (UFR) Santé, Université d'Angers, Angers, France.
Laboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.

Jean-Claude Chomel (JC)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service de Cancérologie Biologique and.

Emilie Cayssials (E)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service d'Oncologie Hématologique et Thérapie Cellulaire, CHU de Poitiers, Poitiers, France.

Maria-Pilar Gallego-Hernanz (MP)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service d'Oncologie Hématologique et Thérapie Cellulaire, CHU de Poitiers, Poitiers, France.

Cédric Pastoret (C)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Laboratoire d'Hématologie, Pôle de Biologie, CHU de Rennes, Rennes, France.

Anne Murati (A)

Laboratoire d'Hématologie et Laboratoire d'Oncologie Moléculaire, Institut Paoli-Calmettes Marseille, Marseille, France.

Frédéric Courtier (F)

Laboratoire d'Hématologie et Laboratoire d'Oncologie Moléculaire, Institut Paoli-Calmettes Marseille, Marseille, France.

Marie-Christine Rousselet (MC)

Département de Pathologie Cellulaire et Tissulaire, CHU Angers, Angers, France.

Isabelle Quintin-Roué (I)

Département de Pathologie Cellulaire et Tissulaire, CHRU Brest, Brest, France.

Laurane Cottin (L)

Université d'Angers, Inserm, CRCINA, Angers, France.
Unité de Formation et de Recherche (UFR) Santé, Université d'Angers, Angers, France.
Laboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.

Corentin Orvain (C)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service des Maladies du Sang, CHU Angers, Angers, France.

Sylvain Thépot (S)

Université d'Angers, Inserm, CRCINA, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service des Maladies du Sang, CHU Angers, Angers, France.

Jean-Marie Chrétien (JM)

DRCI Cellule de Gestion des Données et Evaluation, CHU Angers, Angers, France; and.

Yves Delneste (Y)

Université d'Angers, Inserm, CRCINA, Angers, France.

Norbert Ifrah (N)

Université d'Angers, Inserm, CRCINA, Angers, France.
Unité de Formation et de Recherche (UFR) Santé, Université d'Angers, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service des Maladies du Sang, CHU Angers, Angers, France.

Odile Blanchet (O)

Université d'Angers, Inserm, CRCINA, Angers, France.
Unité de Formation et de Recherche (UFR) Santé, Université d'Angers, Angers, France.
Laboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Centre de Ressources Biologiques, BB-0033-00038, CHU Angers, Angers, France.

Mathilde Hunault-Berger (M)

Université d'Angers, Inserm, CRCINA, Angers, France.
Unité de Formation et de Recherche (UFR) Santé, Université d'Angers, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Service des Maladies du Sang, CHU Angers, Angers, France.

Eric Lippert (E)

Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.
Laboratoire d'Hématologie, CHRU Brest, Brest, France.
Faculté de Médecine, Université de Bretagne Occidentale, Brest, France.

Valérie Ugo (V)

Université d'Angers, Inserm, CRCINA, Angers, France.
Unité de Formation et de Recherche (UFR) Santé, Université d'Angers, Angers, France.
Laboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), Angers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH